(Q24245464)

15

0 references

Benjamin Djulbegovic

11

0 references

Guido Schwarzer

5

0 references

Sven Trelle

7

0 references

Olaf Weingart

8

0 references

Sue Bayliss

9

Susan Bayliss

0 references

Jayne Louise Wilson

2

Jayne Wilson

0 references

Jerome Seidenfeld

3

Jerome Seidenfeld

0 references

Josie Sandercock

6

Josie Sandercock

0 references

Simon Langensiepen

13

Simon Langensiepen

0 references

Chris Hyde

14

Chris Hyde

0 references

Margret Piper

4

Margret Piper

0 references

author name string

Susan Brunskill

10

0 references

Charles Bennett

Cochrane Database of Systematic Reviews

12

0 references

publication date

19 July 2006

0 references

published in

0 references

cites work

Recombinant human erythropoietin in the treatment of the anaemia of cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Impact of epoetin beta on quality of life in patients with malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Erythropoietin increases hemoglobin during radiation therapy for cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Erythropoietin increases hemoglobin in cancer patients during radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

The use of recombinant human erythropoietin to prevent carboplatin-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Erythropoietin treatment in metastatic breast cancer--effects on Hb, quality of life and need for transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Methodologic issues in assessing the quality of life of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Effects of recombinant human erythropoietin on clonogenic growth of primary human tumour specimens in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

A risk-benefit assessment of epoetin in the management of anaemia associated with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Pure red-cell aplasia and epoetin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

The effect of Epoetin alfa on quality of life in anemic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Erythropoietin, uncertainty principle and cancer related anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Expression cloning of the murine erythropoietin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Deep vein thrombosis in cancer: the scale of the problem and approaches to management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Transfusion medicine. Second of two parts--blood conservation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Chemotherapy-induced anemia in adults: incidence and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Prevalence of anemia in cancer patients undergoing radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Erythropoietin in radiation oncology - A review. 1st international conference, Freiburg, June 11-12, 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Estimating the mean and variance from the median, range, and the size of a sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Beneficial and ominous aspects of the pleiotropic action of erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Darbepoetin alfa: a novel erythropoiesis-stimulating protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

The hazards of scoring the quality of clinical trials for meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

The influence of chronic anaemia on the radiosensitivity of two mouse tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Erythropoietin treatment of anemia associated with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

21 January 2018

Symptomatology of anemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Anaemia in cancer: pathophysiology and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Implications of the anemia of chronic disorders in patients anticipating radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Hypoxia and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Explaining heterogeneity in meta-analysis: a comparison of methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Cisplatin-associated anemia: an erythropoietin deficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Is epoetin alfa a treatment option for chemotherapy-related anemia in children?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Fitting autoregressive models for prediction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Erythropoietin for patients undergoing radiotherapy: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Recombinant human erythropoietin for anaemia in Chinese cancer patients on chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Erythropoietin for anaemia in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Breast cancer trial with erythropoietin terminated unexpectedly

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Control of red cell production: the roles of programmed cell death (apoptosis) and erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

The Effect of Alterations in Haematocrit on Tumour Sensitivity to X-rays

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Functional significance of erythropoietin receptor expression in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Relationship between hematocrit and blood pressure: implications for primary hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: preliminary results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Comparison of clinical outcomes of different erythropoietin usage strategies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a ra

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Recombinant human erythropoietin treatment for chemotherapy-related anemia in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021

Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003407.PUB4

7 January 2021